Actinogen Medical in Sydney, Australia | Biotechnology company

Actinogen Medical

Locality: Sydney, Australia

Phone: +61 2 8964 7401

Address: Suite 901, Level 9, 109 Pitt Street 2000 Sydney, NSW, Australia

Website: https://www.actinogen.com.au/

Likes: 217

Add/Update information

Reviews

Tags

• Biotechnology company

24.01.2022 Actinogen partners with Murdoch Children's Research Institute (MCRI) on XanaFX study. The MCRI team of investigators are world leaders in Fragile X research and have considerable expertise in paediatric clinical trials and natural history studies in Fragile X and other rare neurodevelopmental disorders. XanaFX, a Phase II proof-of-concept study, will be conducted at Melbourne Children’s Trials Centre at MCRI and the Royal Children’s Hospital. #fragilexsyndrome #clinicaltrials

23.01.2022 Read Biotech Daily article, Dr Boreham’s Crucible on Actinogen Medical. Find out a brief history of Actinogen, learn about Xanamem’s mechanism of action and discover what else is happening for our studies. This month, Actinogen completed a $7.36m capital raising to support the company to fund a follow-up Alzheimer’s trial, and a study for the new indication of Fragile X syndrome. https://actinogen.com.au//20201120-Biotech-Daily-Nov-20-Dr

22.01.2022 Actinogen Medical Annual General Meeting will be held virtually today at 10.30 am (Sydney time) https://agmlive.link/ACW20

21.01.2022 REGISTER TODAY | Our CEO, Dr Bill Ketelbey, will be presenting at Switzer Small & Micro Cap Virtual Investor Day on 1 Dec 2020 #ASX #investor

21.01.2022 Boardroom.Media CEO, Will Canty speaks with Actinogen (ASX:ACW) CEO & Managing Director, Dr Bill Ketelbey about the upcoming clinical trial in Fragile X syndrome. We are delighted to be involved in this area of research said Dr Bill Ketelbey #investor #clinicaltrials #fragilexsyndrome https://www.boardroom.media/broadcast

17.01.2022 Actinogen is pleased to provide further details on its recent announcements on the clinical development of Xanamem in Fragile X syndrome (FXS), and the upcoming phase II clinical trial XanaFX (‘Xanamem in Fragile X’) in male adolescent FXS patients. XanaFX is a trial of its lead drug candidate, Xanamem, in the treatment of the core symptoms associated with FXS: behavioural problems, anxiety, and sleep. #ASX #xanamem #investor #fragilex https://bit.ly/3kOaUqT

12.01.2022 It is World Diabetes Day Mounting evidence suggest both types of diabetes (Type 1 & 2) are associated with reduced performance in multiple types of cognitive function. Type 2 diabetes has demonstrated a greater overall association with cognitive decline, with a 50% increased risk for dementia and associated impaired attention, processing and motor speed, executive functioning and verbal memory. #cognitiveimpairment #diabetes... https://actinogen.com.au/diabetes/ See more

10.01.2022 Alzheimer’s, diabetes, schizophrenia, depression and a range of diseases present with raised cortisol and decreased cognition. Xanamem is designed to get in to the brain, block the excess production of cortisol and enhance cognition. To find our more: https://actinogen.com.au/xanamem/#mechanism-of-action

07.01.2022 WATCH Dr Bill Ketelbey chats with Rachael Jones at Finance News Network providing an update on Actinogen’s lead drug candidate Xanamem, its clinical trial roadmap and entitlement offer to raise up to $4.9m. https://www.finnewsnetwork.com.au/M/MediaCenterMobile.aspx

05.01.2022 The 1 for 5 non-renounceable entitlement offer for eligible retail shareholders will close at 5.00pm (Sydney time) on Tuesday, 10 November 2020. See further information here: https://actinogen.com.au/investor-centre/

05.01.2022 It’s not too late to register for Switzer Small & Micro Cap Virtual Investor Day. Dr Bill Ketelbey will provide some insight on Actinogen Medical and the Company’s lead drug, Xanamem, designed to enhance cognition through inhibiting cortisol production in the brain, in Alzheimer’s disease and other diseases. Switzer #investor https://zoom.us/webinar/register/WN_IQEA4qg6RIGQlK3pn4tfOQ

04.01.2022 Sonia Madigan from The Market Herald chats with Dr Bill Ketelbey on Actinogen’s two very exciting trials to be initiated next year. XanaMIA, MCI due to Alzheimer’s disease and XanaFX, a smaller trial in Fragile X syndrome. They also discuss the recent capital raising and retail entitlement offer which closes 5.00pm (Sydney time) today. WATCH FROM 4:50 to 13:33

04.01.2022 FXS is caused by a mutation to the FMR1 gene located on the X chromosome. This mutation ‘switches the FMR1 gene off’ and prevents normal brain development. #fragilexsyndrome #fragilex

01.01.2022 Actinogen files two new patent applications. Strengthening our IP portfolio and extending the patent life of protection over Xanamem is aligned with our broader commercialisation strategy for Xanamem Bill Ketelbey View Announcement https://actinogen.com.au//20201109-ASX-2139385-Actinogen-f